HeartBeam Inkomsten in het verleden
Verleden criteriumcontroles 0/6
HeartBeam's earnings have been declining at an average annual rate of -51.5%, while the Medical Equipment industry saw earnings growing at 12.9% annually.
Belangrijke informatie
-51.5%
Groei van de winst
-18.6%
Groei van de winst per aandeel
| Medical Equipment Groei van de industrie | 8.9% |
| Inkomstengroei | n/a |
| Rendement op eigen vermogen | -194.2% |
| Nettomarge | n/a |
| Volgende winstupdate | 07 Nov 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Here's Why We're Watching HeartBeam's (NASDAQ:BEAT) Cash Burn Situation
Sep 19
Companies Like HeartBeam (NASDAQ:BEAT) Could Be Quite Risky
Jan 17HeartBeam gets a new chief medical officer
Oct 11HeartBeam gets patent to enable generation of its credit card-sized ECG, shares rise ~15%
Sep 28HeartBeam surges 54% on U.S. patent for ECG patch monitor to detect heart attacks
Sep 15HeartBeam GAAP EPS of $0.43 beats by $0.70
Aug 11HeartBeam: Cardiovascular Diagnostics On The Go
Dec 14Opbrengsten en kosten
Hoe HeartBeam geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -17 | 9 | 9 |
| 31 Mar 24 | 0 | -15 | 8 | 8 |
| 31 Dec 23 | 0 | -15 | 9 | 7 |
| 30 Sep 23 | 0 | -14 | 9 | 6 |
| 30 Jun 23 | 0 | -15 | 8 | 6 |
| 31 Mar 23 | 0 | -15 | 8 | 7 |
| 31 Dec 22 | 0 | -13 | 7 | 6 |
| 30 Sep 22 | 0 | -11 | 7 | 4 |
| 30 Jun 22 | 0 | -9 | 5 | 3 |
| 31 Mar 22 | 0 | -6 | 3 | 1 |
| 31 Dec 21 | 0 | -4 | 2 | 0 |
| 30 Sep 21 | 0 | -3 | 1 | 0 |
| 30 Jun 21 | 0 | -2 | 1 | 0 |
| 31 Mar 21 | 0 | -1 | 1 | 0 |
| 31 Dec 20 | 0 | -1 | 1 | 0 |
Kwaliteitswinsten: BEAT is currently unprofitable.
Groeiende winstmarge: BEAT is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: BEAT is unprofitable, and losses have increased over the past 5 years at a rate of 51.5% per year.
Versnelling van de groei: Unable to compare BEAT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: BEAT is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (11.7%).
Rendement op eigen vermogen
Hoge ROE: BEAT has a negative Return on Equity (-194.25%), as it is currently unprofitable.